Literature DB >> 24629790

Prevalence and risk of cancer of incidental uptake in prostate identified by fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography.

Zhongyi Yang1, Silong Hu1, Jingyi Cheng1, Junyan Xu1, Wei Shi1, Beiling Zhu1, Yongping Zhang1, Zhifeng Yao1, Herong Pan1, Yingjian Zhang2.   

Abstract

OBJECTIVE: The objective was to investigate the prevalence of incidental fluorine-18 fluorodeoxyglucose (FDG) uptake in positron emission tomography/computed tomography.
METHODS: A total of 11,239 male nonprostate disease patients were included retrospectively.
RESULTS: The prevalence of incidental prostate FDG uptake was approximately 1.8%. Among 198 incidental lesions, 100 patients had further examinations; 20 lesions were confirmed to be malignant, while 80 lesions were benign. After logistic regression analysis, age, site, and the maximum standard uptake value were the potent predictors for differentiation of malignant prostate lesions.
CONCLUSION: When focal FDG uptake in the peripheral zone of prostate is detected, especially in elderly men, further clinical evaluation is recommended.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  (18)F-FDG PET/CT; Incidental; Prostate cancer

Mesh:

Substances:

Year:  2014        PMID: 24629790     DOI: 10.1016/j.clinimag.2014.01.019

Source DB:  PubMed          Journal:  Clin Imaging        ISSN: 0899-7071            Impact factor:   1.605


  11 in total

1.  Multicentre study of 18F-FDG-PET/CT prostate incidental uptake.

Authors:  Francesco Bertagna; Arnoldo Piccardo; Bassam Dib; Mattia Bertoli; Federica Fracassi; Giovanni Bosio; Raffaele Giubbini; Giorgio Biasiotto; Luca Giovanella; Giorgio Treglia
Journal:  Jpn J Radiol       Date:  2015-07-08       Impact factor: 2.374

2.  Case: Incidental 18F-fluorodeoxyglucose-positron emission tomography/computed tomography prostate uptake: How should these patients be managed?

Authors:  Anne Couture; Mounsif Azizi; Daniel Taussky; Michael McCormack
Journal:  Can Urol Assoc J       Date:  2017-07-11       Impact factor: 1.862

3.  Comparison of meta-analyses among elastosonography (ES) and positron emission tomography/computed tomography (PET/CT) imaging techniques in the application of prostate cancer diagnosis.

Authors:  Qiaohong Ouyang; Zhongxiang Duan; Jixiao Lei; Guangli Jiao
Journal:  Tumour Biol       Date:  2015-09-29

4.  Prevalence and clinical significance of incidental (18)F-fluoro-2-deoxyglucose uptake in prostate.

Authors:  Taekmin Kwon; In Gab Jeong; Dalsan You; Jun Hyuk Hong; Hanjong Ahn; Choung-Soo Kim
Journal:  Korean J Urol       Date:  2015-03-20

Review 5.  A Review of Imaging Methods for Prostate Cancer Detection.

Authors:  Saradwata Sarkar; Sudipta Das
Journal:  Biomed Eng Comput Biol       Date:  2016-03-02

6.  Clinical Significance of 18F-Fluorodeoxyglucose Avid Prostate Gland Incidentalomas on Positron Emission Tomography/Computed Tomography.

Authors:  William Makis; Anthony Ciarallo
Journal:  Mol Imaging Radionucl Ther       Date:  2017-06-01

7.  Clinical significance of prostate 18F-labelled fluorodeoxyglucose uptake on positron emission tomography/computed tomography: A five-year review.

Authors:  Madhurima R Chetan; Tristan Barrett; Ferdia A Gallagher
Journal:  World J Radiol       Date:  2017-09-28

8.  Network-directed cis-mediator analysis of normal prostate tissue expression profiles reveals downstream regulatory associations of prostate cancer susceptibility loci.

Authors:  Nicholas B Larson; Shannon K McDonnell; Zach Fogarty; Melissa C Larson; John Cheville; Shaun Riska; Saurabh Baheti; Alexandra M Weber; Asha A Nair; Liang Wang; Daniel O'Brien; Jaime Davila; Daniel J Schaid; Stephen N Thibodeau
Journal:  Oncotarget       Date:  2017-09-08

Review 9.  Clinical implications of PET/CT in prostate cancer management.

Authors:  Kareem N Rayn; Youssef A Elnabawi; Niki Sheth
Journal:  Transl Androl Urol       Date:  2018-10

10.  Prevalence of additional primary malignancies detected incidentally on PET/CT.

Authors:  Joseph C Lee; Marcelo Santos Teles
Journal:  Radiol Bras       Date:  2019 Sep-Oct
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.